Prostamax — Khavinson bioregulator — prostate (injectable pharmaceutical)
Prostamax/Prostatilen is a polypeptide complex from bovine prostate. The pharmaceutical-grade Prostatilen is approved in Russia for prostate conditions. Similar target tissue to Libidon but more data — used clinically for BPH, chronic prostatitis, and male fertility support. Restores prostate cell gene expression, reduces prostatic inflammation, and improves urodynamics.
Overview
This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.
Compound Class
Khavinson bioregulator — prostate (injectable pharmaceutical)
Mechanism of Action
Prostamax/Prostatilen is a polypeptide complex from bovine prostate. The pharmaceutical-grade Prostatilen is approved in Russia for prostate conditions. Similar target tissue to Libidon but more data — used clinically for BPH, chronic prostatitis, and male fertility support. Restores prostate cell gene expression, reduces prostatic inflammation, and improves urodynamics.
Regulatory Status
Not FDA approved in US. Russian pharmaceutical drug (Prostatilen). Approved in Russia for BPH and chronic prostatitis.
Evidence Level
Low-Moderate — Registered pharmaceutical in Russia with clinical data for BPH and prostatitis. More data than Libidon but still limited by Western standards.